Attached files
file | filename |
---|---|
8-K - FORM 8-K - ROCHESTER MEDICAL CORPORATION | c14898e8vk.htm |
Exhibit 99.1
FOR IMMEDIATE RELEASE March 30, 2011 |
Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation
Stewartville, MN March 30, 2011
Rochester Medical Corporation (NASDAQ:ROCM) announced that the shareholders of Fornix BioSciences
N.V. today approved the previously announced sale of Laprolan B.V., its Medical Supplies Division
and wholly owned subsidiary, to Rochester Medical Corporation.
Rochester Medical expects the transaction to close in the near term and, under the terms of the
Share Purchase Agreement between Rochester Medical and Fornix, be deemed retroactive to January 1,
2011. For more information regarding this transaction please refer to the Companys January 12,
2011 press release.
This press release contains forward-looking statements with the meaning of the Private Securities
Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about
the expected completion of the acquisition of Laprolan. Such statements are based on currently
available information, operating plans and managements expectations about future events and
trends. Such statements inherently involve significant risks and uncertainties that could cause
actual results to differ materially from those predicted in such forward-looking statements,
including the risk factors listed from time to time in the Companys SEC reports and filings,
including, without limitation, the section entitled Risk Factors in the Companys Annual Report
on Form 10-K for the year ended September 30, 2010. Readers are cautioned not to place undue
reliance on any such forward-looking statements, which speak only as of the date they are made.
The Company undertakes no obligation to update any forward-looking statements, whether as a result
of new information, future events or otherwise.
Rochester Medical Corporation develops, manufactures, and markets latex-free disposable medical
catheters and devices for urological and continence care applications. The Company markets under
its own Rochester Medical® brand and under existing private label arrangements.
For further information, please contact Anthony J. Conway, President and Chief Executive Officer or
David A. Jonas, Chief Financial Officer of Rochester Medical Corporation at (507) 533-9600. More
information about Rochester Medical is available on its website at http://www.rocm.com.